SCHEMBL4420495

SCHEMBL4420495

NC(C=O)c1ccccn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 2/20 0.45
SLC6A2 P23975 1/20 0.45
SLC6A4 P31645 1/20 0.45
NPSR1 Q6W5P4 1/20 0.43
KDM4E B2RXH2 3/20 0.41
KCNA5 P22460 5/20 0.40
KCNE1 P15382 2/20 0.40
TSHR P16473 2/20 0.40
CYP1A2 P05177 3/20 0.39
CYP3A4 P08684 3/20 0.39
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
ATM Q13315 1/20 0.38
NOS3 P29474 1/20 0.38
NOS1 P29475 1/20 0.38
NOS2 P35228 1/20 0.38
PI4KA P42356 1/20 0.38
PI4K2B Q8TCG2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL248605 0.79 SLC6A2 (0.45) SLC6A3SLC6A2SLC6A4NPSR1KDM4E
SCHEMBL702427 0.79 SLC6A2 (0.45) SLC6A3SLC6A2SLC6A4NPSR1KDM4E
SCHEMBL28803065 0.79 SLC6A3 (0.41) SLC6A3SLC6A2SLC6A4NPSR1KDM4E
SCHEMBL225565 0.78 SLC6A3 (0.48) SLC6A3SLC6A2SLC6A4NPSR1KDM4E
SCHEMBL2579816 0.76
SCHEMBL21495073 0.75 SLC6A3 (0.45) SLC6A3SLC6A2SLC6A4NPSR1KDM4E
SCHEMBL542583 0.75 SLC6A3 (0.45) SLC6A3SLC6A2SLC6A4NPSR1KDM4E
SCHEMBL702800 0.75 CYP3A4 (0.46) SLC6A3SLC6A2SLC6A4NPSR1KDM4E
SCHEMBL11877966 0.75 KDM4E (0.49) SLC6A3SLC6A2SLC6A4NPSR1KDM4E
SCHEMBL16781686 0.75 SLC6A2 (0.54) SLC6A3SLC6A2SLC6A4NPSR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2049522-A2 HEPATITIS C VIRUS INHIBITORS Brystol-Myers Squibb Company (US) 2009-04-22 EP claimed
WO-2008021927-A2 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2008-02-21 WO claimed
US-6737429-B2 TREATMENT OF HIV MEDIATED DISEASES. HOFFMANN-LA ROCHE INC. 2004-05-18 US disclosed
CN-1440385-A Pyrrole derivatives for the treatment of AIDS HOFFMANN LA ROCHE (CH) 2003-09-03 CN disclosed
EP-1301481-A1 PYRROLE DERIVATIVES FOR TREATING AIDS F. HOFFMANN-LA ROCHE AG (CH) 2003-04-16 EP disclosed
US-20020032221-A1 Pyrrole derivatives ROCHE PRODUCTS LIMITED (GB) 2002-03-14 US disclosed
WO-2002002524-A1 PYRROLE DERIVATIVES FOR TREATING AIDS F. HOFFMANN-LA ROCHE AG (CH) 2002-01-10 WO disclosed
US-4895950-A 5-halogeno-6-amino-nicotinic acid halides BAYER AKTIENGESELLSCHAFT (DE) 1990-01-23 US disclosed
EP-0302227-A2 5-Halo-6-amino-nicotinic acid halides, their preparation and their use BAYER AG (DE) 1989-02-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020032221-A1 Pyrrole derivatives PYCR1, SARS1, MAVS SLC6A3 4281/4885SLC6A2 4843/4885SLC6A4 4648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.